Company Overview of Alcobra Ltd.
Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of proprietary pharmaceutical products. The company’ s product candidates include Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy; and Metadoxine Extended Release (MDX), a proprietary oral drug for the treatment of ADHD and other cognitive disorders, including Fragile X syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.
Azrieli Triangle Building
132 Derech Menachem Begin
Tel Aviv, 6701101
Founded in 2008
972 72 220 4661
Key Executives for Alcobra Ltd.
Alcobra Ltd. Key Developments
Similar Private Companies By Industry
|Abital Pharma Pipelines Ltd.||Middle East/Africa|
|Active PX Ltd.||Middle East/Africa|
|Advanced Inhalation Technology Ltd.||Middle East/Africa|
|AIT Therapeutics, Inc.||Middle East/Africa|
|Angio B Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Alcobra Ltd., please visit www.alcobra-pharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.